Monoterpenes are commercially important
flavors and fragrances
with high demand. Microbial production of monoterpenes is more sustainable
than plant extraction, however, it is restricted by high product toxicity/volatility
and inefficient monoterpene synthases. Hence, most reported monoterpene
titers are still low for commercialization. To overcome these challenges,
we utilized the rose NUDIX hydrolase instead of geraniol synthase
to produce geraniol in E. coli. The
supply of the monoterpene precursor, geraniol pyrophosphate (GPP),
was enhanced by the mevalonate pathway optimization and screening/engineering
of various GPP synthases from plants, yeasts, and bacteria. Furthermore,
geraniol production was improved by deleting the competing pathway
genes (tnaA, yjgB, and ackA-pta) and optimizing the bioprocess. The final strain produced 1.05 g/L
monoterpenes in total including 0.91 g/L geraniol in flasks. Moreover,
the geraniol strain was reprogrammed to produce geranyl acetate, reaching
∼4.1 g/L in flasks from 20 g/L glycerol (∼66% of theoretic
yield). We observed that microaerobic fermentation is critical to
achieve high-yield production of geraniol and geranyl acetate. By
controlling the redox potential at −190 mV in 5 L bioreactors,
our strain produced ∼19 g/L geranyl acetate in 100 h, with
a yield of 0.12 g/g-glycerol.